Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franziska Jochims

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Dermatologie (Heidelberg, Germany)|May 11, 2026
[Successful checkpoint inhibition plus extracorporeal photopheresis in patients with metastatic melanoma and advanced Sézary syndrome]Franziska Jochims, Mirjana Ziemer
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 19, 2026
Temporary transfer tattoos and their use in student teaching in dermatology - a monocentric observational studyConrad Hempel, Franziska Jochims, Jan-Christoph Simon, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 26, 2024
A blue faceFranziska Jochims, Benjamin Klein, Jan C Simon, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 1, 2026
Digital transformation and the future of dermatology lectures in 2026 - results of a student survey in LeipzigFranziska Jochims, Daisy Rotzoll, Jan Christoph Simon, et al.
Haematologica|May 9, 2020
Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPPRon Daniel Jachimowicz, Luise Pieper, Sarah Reinke, et al.
Blood|October 28, 2020
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1Sarah Reinke, Paul J Bröckelmann, Ingram Iaccarino, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinomaViola K DeTemple, Martin Kaatz, Eggert Stockfleth, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2025
Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patientsSelma Ugurel, Nessr Abu Rached, Thilo Gambichler, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Dermatologie (Heidelberg, Germany)|May 11, 2026
[Successful checkpoint inhibition plus extracorporeal photopheresis in patients with metastatic melanoma and advanced Sézary syndrome]Franziska Jochims, Mirjana Ziemer
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 19, 2026
Temporary transfer tattoos and their use in student teaching in dermatology - a monocentric observational studyConrad Hempel, Franziska Jochims, Jan-Christoph Simon, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 26, 2024
A blue faceFranziska Jochims, Benjamin Klein, Jan C Simon, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 1, 2026
Digital transformation and the future of dermatology lectures in 2026 - results of a student survey in LeipzigFranziska Jochims, Daisy Rotzoll, Jan Christoph Simon, et al.
Haematologica|May 9, 2020
Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPPRon Daniel Jachimowicz, Luise Pieper, Sarah Reinke, et al.
Blood|October 28, 2020
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1Sarah Reinke, Paul J Bröckelmann, Ingram Iaccarino, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinomaViola K DeTemple, Martin Kaatz, Eggert Stockfleth, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2025
Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patientsSelma Ugurel, Nessr Abu Rached, Thilo Gambichler, et al.
Pageof 1